The Extraordinary General Meeting of Lifecare ASA was convened as a hybrid
meeting on 17 September 2024.
All proposals on the agenda were adopted, cf. the notification of the
Extraordinary General Meeting that was published on Oslo Stock Exchange on 3
September 2024. The complete minutes of the Extraordinary General Meeting are
attached and will be available on https://lifecare.no/investor-relations/
About us
Lifecare ASA is a clinical stage medical sensor company developing technology
for sensing and monitoring of various body analytes. Lifecare's main focus is
to bring the next generation of Continuous Glucose Monitoring ("CGM") systems
to market. Lifecare enables osmotic pressure as sensing principle, combined
with the ability to manipulate Nano-granular Tunnelling Resistive sensors
("NTR") on the sensor body for read-out of pressure variations. Lifecare's
sensor technology is referred to as "Sencell" and is suitable for identifying
and monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.
Contacts
For further information, please contact:
Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40
Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42
This information is subject to disclosure under the Norwegian Securities
Trading Act, ยง5-12. The information was submitted for publication at
2024-09-17 11:00 CEST.